Post-exposure prophylaxis for SIV revisited Animal model for HIV prevention 英文参考文献.docVIP

AIDS Research and Therapy BioMedCentral Research Open Access Post-exposure prophylaxis for SIV revisited: Animal model for HIV prevention Peter Emau*, Yonghou Jiang, Michael B Agy, Baoping Tian, Girma Bekele and Che-Chung Tsai Address: Washington National Primate Research Center, University of Washington, Box 357330 Health Sciences Building, Seattle, Washington 98195, USA Email: Peter Emau* - pemau@; Yonghou Jiang - yhjiang@; Michael B Agy - magy@; Baoping Tian - baoping@; Girma Bekele - girma@; Che-Chung Tsai - cctsai@ * Corresponding author Published: 28 November 2006 Received: 29 August 2006 Accepted: 28 November 2006 AIDS Research and Therapy 2006, 3:29 doi:10.1186/1742-6405-3-29 This article is available from: /content/3/1/29 ? 2006 Emau et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: A 4-week, uninterrupted treatment with 9-(2-phosphonyl-methoxypropyly)adenine (PMPA, commonly called tenofovir) completely prevents simian immunodeficiency virus (SIVmne) infection in cynomolgus macaques if treatment begins within 24 hours after SIVmne inoculation, but is less effective if treatment is delayed or duration of treatment is shortened. Critical factors for efficacy include timing and duration of treatment, potency of antiretroviral drug and a contribution from antiviral immune responses. Therefore, we evaluated the impact of one or more treatment interruptions plus SIVmne re- exposures on efficacy of PMPA treatment to prevent SIVmne infection in cynomolgus macaques. We also evaluated whether macaques with pre-existing SIV immune responses show increased efficacy of treatment. Eight PMPA-treated, virus-negative and seronegative macaques,